| A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (NCT07132983) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2025-10-06 |
| A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD (NCT07016412) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2025-07-31 |
| A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis (NCT06559150) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2024-09-11 |
| A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD (NCT06545500) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2024-08-16 |
| Effect of Ensifentrine Treatment on CAT Score (NCT06460493) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2024-06-11 |
| Effect of Ensifentrine on Sputum Markers of Inflammation in COPD (NCT05270525) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2022-05-27 |
| A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD (NCT04535986) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2020-09-29 |
| A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD (NCT04542057) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2020-09-22 |
| Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD (NCT03937479) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2019-05-01 |
| A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease (NCT04091360) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2019-04-29 |
| Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler (NCT04027439) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2018-12-10 |
| Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD (NCT03673670) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2018-07-16 |
| Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT03443414) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2017-06-01 |
| A Study of RPL554 in Patients With Cystic Fibrosis (NCT02919995) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2017-02-08 |
| The Effects of RPL554 in Addition to Tiotropium in COPD Patients (NCT03028142) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2017-01-01 |
| The Effects of RPL554 on Top of Standard COPD Reliever Medications (NCT02542254) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2015-10-01 |
| Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients (NCT02427165) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2015-04-01 |
| SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects (NCT02307162) | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2014-12-01 |